177 related articles for article (PubMed ID: 29153245)
1. Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide.
Klaassen SHC; Tromp J; Nienhuis HLA; van der Meer P; van den Berg MP; Blokzijl H; van Veldhuisen DJ; Hazenberg BPC
Am J Cardiol; 2018 Jan; 121(1):107-112. PubMed ID: 29153245
[TBL] [Abstract][Full Text] [Related]
2. Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure?
Jonker DL; Hazenberg BPC; Nienhuis HLA; Slart RHJA; Glaudemans AWJM; Noordzij W
J Nucl Cardiol; 2020 Oct; 27(5):1774-1784. PubMed ID: 30374850
[TBL] [Abstract][Full Text] [Related]
3. Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis.
Damy T; Deux JF; Moutereau S; Guendouz S; Mohty D; Rappeneau S; Guellich A; Hittinger L; Loric S; Lefaucheur JP; Plante-Bordeneuve V
Amyloid; 2013 Dec; 20(4):212-20. PubMed ID: 23964755
[TBL] [Abstract][Full Text] [Related]
4. Incremental value of high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients.
Goei D; Hoeks SE; Boersma E; Winkel TA; Dunkelgrun M; Flu WJ; Schouten O; Bax JJ; Poldermans D
Coron Artery Dis; 2009 May; 20(3):219-24. PubMed ID: 19322079
[TBL] [Abstract][Full Text] [Related]
5. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System.
Grogan M; Scott CG; Kyle RA; Zeldenrust SR; Gertz MA; Lin G; Klarich KW; Miller WL; Maleszewski JJ; Dispenzieri A
J Am Coll Cardiol; 2016 Sep; 68(10):1014-20. PubMed ID: 27585505
[TBL] [Abstract][Full Text] [Related]
6. Plasma N-terminal pro-B-type natriuretic peptide as a predictor of perioperative and long-term outcome after vascular surgery.
Schouten O; Hoeks SE; Goei D; Bax JJ; Verhagen HJ; Poldermans D
J Vasc Surg; 2009 Feb; 49(2):435-41; discussion 441-2. PubMed ID: 19028043
[TBL] [Abstract][Full Text] [Related]
7. Limitations of N-Terminal Pro-B-Type Natriuretic Peptide in the Diagnosis of Heart Disease among Cancer Patients Who Present with Cardiac or Pulmonary Symptoms.
Wieshammer S; Dreyhaupt J; Müller D; Momm F; Jakob A
Oncology; 2016; 90(3):143-50. PubMed ID: 26871423
[TBL] [Abstract][Full Text] [Related]
8. Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis.
Cappelli F; Baldasseroni S; Bergesio F; Perlini S; Salinaro F; Padeletti L; Attanà P; Paoletti Perini A; Moggi Pignone A; Grifoni E; Fabbri A; Marchionni N; Gensini GF; Perfetto F
Clin Cardiol; 2015 Feb; 38(2):69-75. PubMed ID: 25645201
[TBL] [Abstract][Full Text] [Related]
9. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of N-terminal natriuretic peptides in systemic sclerosis: a single centre study.
Költő G; Vuolteenaho O; Szokodi I; Faludi R; Tornyos A; Ruskoaho H; Minier T; Czirják L; Komócsi A
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-75-81. PubMed ID: 25372791
[TBL] [Abstract][Full Text] [Related]
11. Different NT-proBNP circulating levels for different types of cardiac amyloidosis.
Perfetto F; Bergesio F; Grifoni E; Fabbri A; Ciuti G; Frusconi S; Angelotti P; Spini V; Cappelli F
J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):810-7. PubMed ID: 26765991
[TBL] [Abstract][Full Text] [Related]
12. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.
Palladini G; Campana C; Klersy C; Balduini A; Vadacca G; Perfetti V; Perlini S; Obici L; Ascari E; d'Eril GM; Moratti R; Merlini G
Circulation; 2003 May; 107(19):2440-5. PubMed ID: 12719281
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems.
Cappelli F; Martone R; Gabriele M; Taborchi G; Morini S; Vignini E; Allinovi M; Di Gioia M; Bartolini S; Di Mario C; Perfetto F
Can J Cardiol; 2020 Mar; 36(3):424-431. PubMed ID: 32145869
[TBL] [Abstract][Full Text] [Related]
14. Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).
Kristen AV; Maurer MS; Rapezzi C; Mundayat R; Suhr OB; Damy T;
PLoS One; 2017; 12(4):e0173086. PubMed ID: 28384285
[TBL] [Abstract][Full Text] [Related]
15. N-terminal pro-brain natriuretic peptide and angiotensin-converting enzyme-2 levels and their association with postoperative cardiac complications after emergency orthopedic surgery.
Chong CP; Lim WK; Velkoska E; van Gaal WJ; Ryan JE; Savige J; Burrell LM
Am J Cardiol; 2012 May; 109(9):1365-73. PubMed ID: 22381157
[TBL] [Abstract][Full Text] [Related]
16. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
Solomon SD; Adams D; Kristen A; Grogan M; González-Duarte A; Maurer MS; Merlini G; Damy T; Slama MS; Brannagan TH; Dispenzieri A; Berk JL; Shah AM; Garg P; Vaishnaw A; Karsten V; Chen J; Gollob J; Vest J; Suhr O
Circulation; 2019 Jan; 139(4):431-443. PubMed ID: 30586695
[TBL] [Abstract][Full Text] [Related]
17. Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis.
Aljama MA; Sidiqi MH; Dispenzieri A; Gertz MA; Lacy MQ; Buadi FK; Dingli D; Muchtar E; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Warsame RM; Kourelis T; Hwa YL; Kapoor P; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
Blood Adv; 2019 Apr; 3(8):1226-1229. PubMed ID: 30975646
[TBL] [Abstract][Full Text] [Related]
18. Non-Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis.
Hirakawa K; Takashio S; Marume K; Yamamoto M; Hanatani S; Yamamoto E; Sakamoto K; Izumiya Y; Kaikita K; Oda S; Utsunomiya D; Shiraishi S; Ueda M; Yamashita T; Yamashita Y; Ando Y; Tsujita K
ESC Heart Fail; 2019 Feb; 6(1):122-130. PubMed ID: 30284755
[TBL] [Abstract][Full Text] [Related]
19. The interrelationship between preoperative anemia and N-terminal pro-B-type natriuretic peptide: the effect on predicting postoperative cardiac outcome in vascular surgery patients.
Goei D; Flu WJ; Hoeks SE; Galal W; Dunkelgrun M; Boersma E; Kuijper R; van Kuijk JP; Winkel TA; Schouten O; Bax JJ; Poldermans D
Anesth Analg; 2009 Nov; 109(5):1403-8. PubMed ID: 19843778
[TBL] [Abstract][Full Text] [Related]
20. Utility of B-Type Natriuretic Peptide for Detecting Cardiac Involvement in Immunoglobulin Amyloidosis.
Kimishima Y; Yoshihisa A; Kiko T; Yokokawa T; Miyata-Tatsumi M; Misaka T; Oikawa M; Kobayashi A; Takeishi Y
Int Heart J; 2019 Sep; 60(5):1106-1112. PubMed ID: 31484874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
